Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1987 Jan-Feb;15(1):20-4.
doi: 10.1007/BF01646113.

[Clinical study of the effectiveness and tolerance of norfloxacin in the therapy of complicated urinary tract infections and in long-term prevention of recurrent urinary tract infections]

[Article in German]

[Clinical study of the effectiveness and tolerance of norfloxacin in the therapy of complicated urinary tract infections and in long-term prevention of recurrent urinary tract infections]

[Article in German]
M Westenfelder et al. Infection. 1987 Jan-Feb.

Abstract

The efficacy and tolerance of norfloxacin in the treatment of complicated urinary tract infections and in low dose long-term prophylaxis over six months for recurrent UTI were investigated in 60 and 27 patients, respectively. In the prophylaxis group, compliance with medication was controlled weekly using Mecur BT. Five to nine days after treatment, the urine was sterile in 50 out of the 60 patients treated (83.3%); relapse occurred in six patients and was associated with development of resistance in two. Four patients suffered re-infection within the study period. Failure of treatment was closely related to persisting complicating factors in the urinary tract. The overall tolerance of norfloxacin was satisfactory. However, there was one severe allergic reaction. During the total 391 weeks of low dose long-term prophylaxis given to 27 patients, only one break-through infection occurred. Yet compliance studies proved that antimicrobial activity was present in the urines of less than 50% of the patients. During prophylaxis, the rate of infection was reduced from three to four to 0.13 to 0.05 infections/patient/year. There was no development of resistance in the isolates from these patients. Only two adverse reactions were observed.

PubMed Disclaimer

References

    1. MMW Munch Med Wochenschr. 1983 Aug 5;125(31):694-6 - PubMed
    1. J Antimicrob Chemother. 1986 May;17 Suppl C:97-102 - PubMed
    1. Infection. 1983 Nov-Dec;11(6):296-301 - PubMed
    1. J Antimicrob Chemother. 1984 May;13 Suppl B:113-20 - PubMed
    1. J Urol. 1961 Dec;86:739-48 - PubMed

Publication types

LinkOut - more resources